Abstract: Revumenib (SNDX-5613) is a novel, first-in-class, orally bioavailable small-molecule menin inhibitor that has recently transformed the therapeutic landscape for specific high-risk acute leukemias. It is specifically designed to target acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) driven by lysine methyltransferase 2A rearrangements (KMT2Ar) or nucleophosmin 1 (NPM1) mutations. By selectively disrupting the protein-protein interaction between menin and the KMT2A complex, revumenib halts the aberrant transcription of leukemogenic genes, notably the HOXA cluster and MEIS1, thereby relieving differentiation blockade and inducing terminal differentiation of leukemic blasts. Clinical trials, most notably the AUGMENT-101 study, have demonstrated profound efficacy, achieving high rates of composite complete remission and measurable residual disease (MRD) negativity in heavily pretreated relapsed/refractory populations, leading to its recent FDA approval. While revumenib exhibits a manageable safety profile, its use is associated with specific adverse events, including QTc prolongation and differentiation syndrome, as well as the potential for acquired resistance via MEN1 mutations. Current research is rapidly expanding its application into frontline combination regimens and post-transplant maintenance, marking a significant milestone in precision oncology for acute leukemia.
1. Introduction
Acute myeloid leukemia (AML) is a molecularly heterogeneous neoplasm characterized by the rapid proliferation of poorly differentiated myeloid blasts. Despite advances in treatment, certain genetic subsets of acute leukemia—specifically those harboring lysine methyltransferase 2A rearrangements (KMT2Ar, formerly MLL) or nucleophosmin 1 (NPM1) mutations—have historically been associated with poor clinical outcomes, particularly in the relapsed or refractory (R/R) setting [8][16]. KMT2Ar occurs in approximately 5-10% of AML and ALL cases and is notorious for its dismal prognosis, with a median overall survival (OS) of merely 2.4 months and a complete remission (CR) rate of about 5% in R/R patients [7][8]. NPM1 mutations are the most common genetic variation in adult AML, accounting for up to 30% of cases; while initial responses to chemotherapy are high, nearly 50% of patients eventually relapse [7][8].
Both KMT2Ar and NPM1-mutated (NPM1m) leukemias share a common pathogenetic dependency on the aberrant activation of the MEIS1-HOXA transcriptional axis, which is mediated by the chromatin adapter protein menin [8][12]. Revumenib (SNDX-5613) is a first-in-class, targeted small-molecule inhibitor designed to disrupt the menin-KMT2A interaction [1][6]. Based on compelling efficacy and safety data from the pivotal AUGMENT-101 trial, revumenib received FDA approval in late 2024 and early 2025 for the treatment of R/R acute leukemia with KMT2A translocations and NPM1 mutations in adult and pediatric patients aged one year and older [3][4][8][12][13].
2. Pharmacological Activity
Revumenib has demonstrated robust antileukemic activity both as a monotherapy and in combination regimens. In the pivotal phase I/II AUGMENT-101 trial (NCT04065399) evaluating revumenib monotherapy in heavily pretreated R/R KMT2Ar and NPM1m acute leukemias, the drug yielded an overall response rate (ORR) of 53% to 64% [1][6][8][13]. The composite complete remission (CRc, including CR and CR with partial hematologic recovery [CRh]) rate was approximately 23% to 30% [8][12]. Crucially, among the responders, 61% to 78% achieved measurable residual disease (MRD) negativity, indicating deep molecular remissions [6][8][13]. This deep response allowed 34% to 39% of responding patients to successfully bridge to potentially curative allogeneic hematopoietic stem cell transplantation (allo-HSCT) [6][8][13].
Beyond monotherapy, revumenib exhibits significant synergistic pharmacological activity when combined with other agents. In the AUGMENT-102 trial, combining revumenib with fludarabine and cytarabine (FLA) in R/R AML yielded a CRc of 51% and an MRD negativity rate of 71% [8]. The SAVE trial (NCT05360160) investigated an all-oral triplet regimen of revumenib, decitabine/cedazuridine (ASTX727), and venetoclax, reporting an ORR of 82% to 88% and MRD negativity in up to 100% of responders [11][12][13]. Furthermore, in the frontline setting for older, newly diagnosed patients (BEAT AML trial), revumenib combined with azacitidine and venetoclax achieved an ORR of 88.4% and a CRc of 81.4%, with 100% of evaluated patients achieving MRD negativity [12][13]. Revumenib has also shown pharmacological efficacy in other rare leukemias dependent on HOX upregulation, such as those with NUP98 rearrangements [6][12].
3. Molecular Mechanism of Action
The therapeutic efficacy of revumenib is rooted in its ability to act as a targeted epigenetic modulator. In normal hematopoiesis, menin is a nuclear scaffold protein that interacts with the KMT2A complex to regulate gene expression [6][7]. In KMT2Ar leukemias, chromosomal translocations create fusion proteins that retain the menin-binding domain. Menin tethers these aberrant KMT2A fusion proteins to chromatin, leading to the hyperactivation of specific target genes [7][9]. Similarly, in NPM1m AML, the cytoplasmic dislocation of mutant NPM1 paradoxically relies on the wild-type menin-KMT2A complex to drive leukemogenesis [4][7].
Revumenib functions by selectively binding to menin, thereby physically disrupting the protein-protein interaction between menin and KMT2A (or KMT2A fusion proteins) [5][9]. This disruption evicts the KMT2A complex from chromatin, which rapidly halts the oncogenic transcription of the HOXA gene cluster (e.g., HOXA9) and its critical cofactor MEIS1 [5][8][12]. The downregulation of the HOXA/MEIS1 transcriptional program removes the block on hematopoietic differentiation. Consequently, leukemic blasts undergo terminal differentiation into mature myeloid cells followed by apoptosis [5][9][11]. This mechanism is clinically observable; patients often exhibit morphological remission where mature cells still temporarily harbor the underlying cytogenetic abnormality before eventual cytogenetic clearing [6][8].
4. Structure-Activity Relationship (SAR)
Revumenib (formerly SNDX-5613) was developed as a highly potent, orally bioavailable analog of the preclinical menin inhibitor VTP-50469 [6][10]. Structurally, revumenib is designed to fit precisely into a highly conserved binding pocket located at the N-terminal of the menin protein [6]. By occupying this specific pocket, revumenib sterically hinders the binding of the KMT2A protein, which is essential for the complex's chromatin-targeting capabilities [6][7].
A distinguishing feature of revumenib's SAR compared to other emerging menin inhibitors is its mechanism of target engagement. While some menin inhibitors have been shown to induce the degradation of the menin protein itself, revumenib acts purely as a displacement agent, inhibiting the interaction without causing menin degradation [6]. Pharmacokinetically, the structure of revumenib makes it a major substrate of the cytochrome P450 3A4 (CYP3A4) pathway. This metabolic profile necessitates split-dose escalation and careful dose adjustments in clinical practice, particularly when co-administered with strong CYP3A4 inhibitors such as azole antifungals (e.g., posaconazole, voriconazole), which significantly alter its clearance [5][6][8].
5. Current Limitations
Despite its breakthrough efficacy, the clinical utility of revumenib is constrained by specific toxicities and the emergence of drug resistance:
- QTc Prolongation: The most prominent dose-limiting toxicity (DLT) of revumenib is asymptomatic prolongation of the QTc interval on electrocardiography. This occurs in 40% to 56% of patients, with grade 3 or 4 events seen in 13% to 20% of cases [6][8][11][12]. While generally reversible and manageable via electrolyte repletion and dose modifications, it requires rigorous cardiac monitoring [6][8].
- Differentiation Syndrome (DS): Because revumenib induces blast maturation, it can trigger DS, characterized by leukocytosis, fever, hypoxia, and pulmonary infiltrates. DS occurs in 15% to 27% of patients (mostly grade 2) and requires prompt recognition and intervention with corticosteroids and hydroxyurea to prevent life-threatening complications [6][8][11].
- Cytopenias and Infections: High rates of grade ≥3 treatment-emergent adverse events (TEAEs) are reported, including febrile neutropenia (14-39%), thrombocytopenia (16-63%), and anemia (16-56%), which can complicate the treatment course [6][8][11][12].
- Acquired Resistance: A major limitation to the durability of revumenib is the development of acquired resistance. Approximately 40% of patients who relapse develop somatic mutations in the MEN1 gene (e.g., M327I) at the drug-binding interface. These mutations alter the binding pocket, preventing revumenib from displacing KMT2A and leading to morphological relapse [5][11][13].
6. Future Perspectives
The future trajectory for revumenib and the broader class of menin inhibitors is highly promising, with research expanding across several fronts. First, there is a strong push to move revumenib into the frontline setting. Ongoing trials are evaluating its efficacy in newly diagnosed patients in combination with intensive induction chemotherapy (7+3 regimen) or with lower-intensity backbones like venetoclax and azacitidine, aiming to achieve deeper initial remissions and prevent relapse [8][12][13]. Second, revumenib is being actively investigated as a post-transplant maintenance therapy to sustain MRD negativity and prevent disease recurrence in high-risk populations [8][10].
To address the challenge of acquired resistance, next-generation menin inhibitors, including covalent binders (e.g., BMF-219/icovamenib) and menin degraders, are in preclinical and early clinical development. These agents aim to bypass the point mutations at the binding interface that render revumenib ineffective [9][13]. Finally, the therapeutic scope of menin inhibitors is broadening. Evidence suggests that revumenib may be effective in other leukemias characterized by HOXA/MEIS1 upregulation, such as NUP98-rearranged AML, and may even play a role in overcoming acquired resistance to venetoclax-based therapies, highlighting its potential as a versatile backbone in precision hematology [6][7][12].
